Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Análisis de sangre rápido para predecir la respuesta de la tensión arterial al tratamiento de presión positiva continua de las vías respiratorias (CPAP) en pacientes con hipertensión resistente y apnea obstructiva del sueño

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20151221001
Publicado:
15/01/2016
Caducidad:
15/01/2017
Resumen:
Un consorcio español especializado en enfermedades respiratorias ha desarrollado un método que determina de forma predectiva si un paciente con hipertensión resistente y apnea obstructiva del sueño responde positivamente al tratamiento de presión positiva continua de las vías respiratorias (CPAP), reduciendo la presión arterial. Este nuevo método presenta el CPAP como nuevo tratamiento rentable para pacientes con hipertensión resistente. El equipo busca compañías con el fin de establecer acuerdos de licencia o cooperación técnica.

Details

Tittle:
Quick blood sample test for predicting blood pressure response to continuous positive airway pressure (CPAP) treatment in patients with resistant hypertension and obstructive sleep apnoea.
Summary:
A Spanish consortium specialised in respiratory diseases has developed a method that can predictively determine if a patient with resistant hypertension and obstructive sleep apnoea positively responds to continuous positive air pressure treatment (CPAP), lowering blood pressure. The new method presents CPAP as a new treatment to resistant hypertension patients in a cost-effective manner. The group is looking for companies for license or technical cooperation agreement.
Description:
Patients with resistant hypertension (RH) do not respond to any treatment for their blood pressure control despite being treated with three drugs or more. Continuous Positive Air Pressure (CPAP) therapy is a new therapeutic alternative for the control of blood pressure in 70-75% of patients with RH and obstructive sleep apnoea (OSA) (80% of patients with RH suffer OSA). Nonetheless, for an unknown reason, there are a 25-30% of patients with OSA that do not respond (no change in blood pressure or even an increase after CPAP). Moreover, CPAP is a chronic treatment that could have secondary adverse effects or even deleterious to non-responder patients.
Currently there is no method for predicting response of RH patients to CPAP treatment and there is a need to identify those responder patients that would benefit from this treatment.
The predictive identification of the responders will avoid costs and time with the non-responders, who could be derived to other therapies. Moreover secondary adverse effects or even deleterious effects in non-responders could be also avoided.

A Spanish consortium has developed a method to predict with high specificity and reliability whether a RH patient with OSA could reduce his blood pressure to normal values using a CPAP treatment. The methodology uses the expression analysis of 3 microRNAs in a peripheral blood sample of the patient in order to define his/her specific expression profile, and the application of a score. The method has been obtained from data of a multicentre, randomized clinical trial study to evaluate the effect of CPAP treatment on blood pressure values in patients with RH and OSA.
The present invention addresses the healthcare market for RH and OSA patients. It offers a new treatment for an approximately 50% of RH patients, that is not currently offered directly in hypertension units, in a cost-effective manner.

The group that has developed this method, has extensive scientific and technical expertise in multicenter studies in the field of sleep breathing disorders. It is a Spanish multidisciplinary team that has demonstrated its ability to correctly pursue both clinical and basic objectives generating a large number of high impact publications.
License agreements and /or technical cooperation agreements with a biotech, biopharmaceutical, diagnosis, oxygen providers or services companies based on this invention are sought to co-develop the clinical diagnostic kit and its commercialization.
Advantages and Innovations:
- Permits the CPAP to emerge as a new therapeutic alternative for the control of blood pressure in patients with HR and OSA.

- Currently it is the only technique that can evaluate the blood pressure response to CPAP for RH and OSA patients.

- Is a very quick (hours), cheap, and minimally invasive method (blood sample).

- Is highly reliable, with high values of sensibility and specificity

- Identifies RH patients that can benefit from CPAP treatment.

- Offers CPAP treatment to HR and OSA patients for their arterial blood pressure control in a cost-effective manner.

- Reduces economic costs to health providers limiting the CPAP treatment to patients that positively respond.

- It is easily applicable to clinical practice, due to the provision of a quantitative score parameter informing the clinician of the probability of response to CPAP treatment for a particular patient.

- It can reduce time and avoid additional complications in non-responders.
Stage of Development:
Field tested/evaluated
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
European patent application filed, PCT extension in process

Partner sought

Type and Role of Partner Sought:
Diagnostic, biotech or pharmaceutical companies, oxygen devices providers or clinical test service providers for co-development and commercialization of the product.

Specific roles should be the development of a clinical diagnostic kit or service and the commercialization, distribution and collaboration in studies for broader applications of the technology in different patient populations.

The specific area of activity of the partner should be in health interested in cardiovascular diseases, continuous positive airway pressure, and/or sleep apnoea, and diagnosis and treatment prediction.

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
French
Spanish

Keywords

Technology Keywords:
06001011 Enfermedades circulatorias y del corazón
06003002 Expresión genética, investigación proteómica
06001013 Tecnología médica / ingeniería biomédica